- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pam Mangat Discusses ASCO's Progress on TAPUR Study
The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology.
The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology (ASCO).
Transcript (slightly modified)
Has ASCO been receiving field data from the TAPUR trial? What results has ASCO seen so far?
ASCO first announced that they would be undertaking a clinical trial in June of 2015, and we launched the study, you know, a short 9 months later, with 37 clinical site locations primarily based in Michigan and North Carolina as our launch sites, to ensure that our processes and procedures worked as anticipated. And the good news is we’ve done that, and now we’re starting to grow. So we’re expanding to another 25 sites and we hope to be by 100 sites by the end of next year.
So all of this is to say that we are collecting data right now from a wide variety of clinical sites, but we don’t have the trial results yet published. But we do have an external data monitoring committee that, once we have cohorts full enough to analyze data, they will take a look at these data points and approve whether or not we would be able to release that. But we have a goal of releasing this data and releasing it to the public as soon as we are able to.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
